PRMT5 as a Novel Druggable Vulnerability for EWSR1-ATF1-driven Clear Cell Sarcoma
B. X. Li, X. Xiao, L. L. David, L. E. Davis
This study identifies PRMT5 as a druggable target for EWSR1-ATF1-driven clear cell sarcoma, showing that its inhibition reduces tumor cell growth.
bioRxiv · Mar 23, 2022 · PreprintCancer Biology